

Supplementary Table S1. Ongoing treatment in SSc patients according to the NVC patterns (“Early”, “Active” and “Late”).

	SSc (n=43)	Pt with “Early” NVC pattern (n=11)	Pt with “Active” NVC pattern (n=16)	Pt with “Late” NVC pattern (n=16)	p-value
PDN, n (%)	5 (11.6)	0 (0)	2 (12.5)	3 (18.75)	ns
PPI, n (%)	39 (90.7)	9 (81.82)	15 (93.75)	15 (93.75)	ns
CCB, n (%)	12 (27.9)	4 (36.4)	2 (12.5)	6 (37.5)	ns
ACEi, n (%)	18 (41.9)	3 (27.27)	9 (26.52)	6 (37.5)	ns
ARBs, n (%)	5 (11.6)	3 (27.27)	1 (6.25)	1 (6.25)	ns
Iloprost, n (%)	40 (93)	11 (100)	14 (87.5)	15 (93.75)	ns
ASA, n (%)	31 (72)	9 (81.81)	9 (56.25)	13 (81.25)	ns
PD5I, n (%)	5 (11.6)	0 (0)	3 (18.75)	2 (12.5)	ns
ERA, n (%)	14 (32.5)	0 (0)	4 (25)	10 (62.5)	0.002
MTX, n (%)	9 (20.9)	1 (9.1)	5 (31.25)	3 (18.75)	ns
MMF, n (%)	11 (25.6)	0 (0)	4 (25)	7 (43.75)	0.038
CSA, n (%)	9 (20.9)	2 (18.2)	4 (25)	3 (18.75)	ns
Cholecalciferol, n (%)	38 (88.4)	9 (81.81)	13 (81.25)	16 (100)	ns
Bisphosphonates, n (%)	7 (16.3)	3 (27.27)	2 (12.5)	2 (12.5)	ns
Denosumab, n (%)	1 (2.3)	0 (0%)	0 (0)	1 (6.25)	ns

PDN: prednisone (maximum dose of 5 mg/day); PPI: proton pump inhibitors (lansoprazole 15-30 mg/pantoprazole 20-40 mg/day); CCB: calcium channel blockers (amlodipine 5 mg/day); Acei: Ace inhibitors (ramipril 5-10mg/day); Iloprost (median 2 days/month); ASA: acetylsalicylic acid (75-100mg/day); PD5I: phosphodiesterase type 5 inhibitors (sildenafil 60 mg/day); ERA: endotelin receptor antagonists (tracleer 250 mg/day); MTX: methotrexate (7.5-10 mg/week); MMF: mycophenolate mofetil (1.5-2 g/day); CSA: cyclosporine (150-200 mg/day); Cholecalciferol (median dose >1500 U/day); Bisphosphonates (alendronate 70 mg/week-risedronate 35 mg/week). Denosumab (60mg/6 months).

Supplementary Table S2. Median values of SSc patient’s laboratory tests and differences in the three subgroups according to the NVC patterns (“Early”, “Active” and “Late”).

	SSc (n=43)	Pt with “Early” NVC pattern (n=11)	Pt with “Active” NVC pattern (n=16)	Pt with “Late” NVC pattern (n=16)	p-value
<i>Laboratory tests</i>					
Hb, media ± SD, g/dL	12.7 ± 1.3	12.7 ± 0.8	13 ± 1.5	12.3 ± 1.3	ns
Crea, media ± SD, mg/dL	0.85 ± 0.22	0.82 ± 0.16	0.91 ± 0.2	0.8 ± 0.27	ns
CK, median (IQR), U/I	76 (24-485)	84 (44-485)	56 (32-312)	66.5 (24-219)	ns
CRP, median (IQR), mg/dL	3.1 (2-10)	3.2 (2.6-8.4)	3.1 (1-12.6)	3.1 (0.9-13.8)	ns
25OH VIT-D, median (IQR), ng/ml	33.9 (4.6-48)	34.8 (9.8-48)	30.6 (4.6-44)	35.3 (19.3-42.8)	ns
Ca, median (IQR), mg/dL	9.5 (8.1-11.6)	9.8 (8.9-10.2)	9.45 (9-10)	9.45 (1.6-10)	ns
Ph, media ± SD, mg/dL	3.34 ± 0.54	3.36 ± 0.6	3.33 ± 0.48	3.33 ± 0.6	ns
BAP, median (IQR), ug/L	8 (2.5-33.4)	5.7 (3-14.3)	8.75 (4.7-41)	10.1 (2.4-33)	ns
ANA positivity, n (%)	42 (97.7)	11 (100)	15 (93.75)	16 (100)	ns
Anti-Scl70 positivity, n (%)	17 (39.5)	7 (63.6%)	7 (43.75%)	3 (18.75)	ns
Anti-cenp A, B positivity, n (%)	16 (37.2)	4 (36.4)	4 (25%)	8 (50)	ns

Hb: haemoglobin; Crea: creatinine; CK: creatine kinase; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; 25OH VIT-D: 25hydroxyvitamin-D; Ca: calcium; Ph: phosphorus; BAP: bone alkaline phosphatase.